Physician profile
Donatus Weithman
NPI 1346317385
$4,451.45
in general payments reported to CMS, 2019-2025
33 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,220 · 2020: $544 · 2021: $1,423 · 2022: $1,228 · 2023: $36.51.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $36.51.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $36.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,065.28 | 2019-2023 | Wegovy |
| Lilly USA, LLC | $443.79 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $394.06 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $342.71 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $286.82 | 2019-2022 | |
| Abbvie INC. | $243.06 | 2021-2022 | |
| Amgen INC. | $179.33 | 2019-2022 | |
| Pfizer INC. | $178.98 | 2019-2022 | |
| Glaxosmithkline, LLC. | $143.75 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $110.85 | 2019-2023 | Airduo Digihaler |
| Merck Sharp & Dohme LLC | $104.48 | 2019-2021 | |
| Allergan, INC. | $99.99 | 2019-2021 | |
| Eisai INC. | $97.44 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $89.93 | 2019-2021 | |
| Currax Pharmaceuticals LLC | $86.17 | 2020-2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cranial Technologies, INC | $75.99 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $60.43 | 2019-2020 | |
| Genentech USA, INC. | $49.72 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $40.49 | 2019 | |
| Sobi, INC | $39.69 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $39.66 | 2022 | |
| Astellas Pharma US INC | $37.25 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $32.35 | 2019-2022 | |
| Adlon Therapeutics L.P. | $31.98 | 2020-2021 | |
| Shire North American Group INC | $24.54 | 2019 | |
| Amarin Pharma, INC. | $24.33 | 2021-2022 | |
| Esperion Therapeutics, INC. | $22.62 | 2021 | |
| Sanofi Pasteur INC. | $21.75 | 2022 | |
| Idorsia Pharmaceuticals US INC | $21.29 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $20.59 | 2019 | |
| Hikma Pharmaceuticals USA | $16.65 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.12 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $11.36 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donatus Weithman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.